

# Joseph S. Ross

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6806430/joseph-s-ross-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150 papers	8,524 citations	42 h-index	91 g-index
165 ext. papers	10,063 ext. citations	13.8 avg, IF	5.98 L-index

#	Paper	IF	Citations
150	Exposure to low-dose ionizing radiation from medical imaging procedures. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 849-57	59.2	1001
149	Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 355-63	27.4	653
148	Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 303, 2141-7	27.4	485
147	An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2008</b> , 1, 29-37	5.8	391
146	Recent national trends in readmission rates after heart failure hospitalization. <i>Circulation: Heart Failure</i> , <b>2010</b> , 3, 97-103	7.6	326
145	National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 1116-24	11.5	270
144	Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 299, 1800-12	27.4	266
143	Trial publication after registration in ClinicalTrials.gov: a cross-sectional analysis. <i>PLoS Medicine</i> , <b>2009</b> , 6, e1000144	11.6	262
142	Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 587-93	27.4	256
141	Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 368-77	27.4	244
140	Hospital volume and 30-day mortality for three common medical conditions. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1110-8	59.2	244
139	Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. <i>BMJ, The</i> , <b>2012</b> , 344, d7292	5.9	238
138	Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 302, 767-73	27.4	196
137	Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013. <i>Diabetes Care</i> , <b>2017</b> , 40, 468-475	14.6	181
136	Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 2647-2656	27.4	175
135	Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 317, 1854-1863	27.4	164
134	Cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures: a population-based analysis. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 702-11	15.1	143

133	National patterns of risk-standardized mortality and readmission for acute myocardial infarction and heart failure. Update on publicly reported outcomes measures based on the 2010 release. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2010</b> , 3, 459-67	5.8	133
132	Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 734-745	27.4	132
131	Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 270-278	27.4	127
130	Effect of blinded peer review on abstract acceptance. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 1675-80	27.4	119
129	Regulatory review of novel therapeutics--comparison of three regulatory agencies. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 2284-93	59.2	118
128	Health care insurance, financial concerns in accessing care, and delays to hospital presentation in acute myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 303, 1392-400	27.4	96
127	Ushering in a new era of open science through data sharing: the wall must come down. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1355-6	27.4	77
126	Hospital-Readmission Risk - Isolating Hospital Effects from Patient Effects. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1055-1064	59.2	72
125	Use of ezetimibe in the United States and Canada. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 1819-28	59.2	70
124	Time to publication among completed clinical trials. <i>JAMA Internal Medicine</i> , <b>2013</b> , 173, 825-8	11.5	64
123	Reporting of results in ClinicalTrials.gov and high-impact journals. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 1063-5	27.4	62
122	Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 604-12	27.4	59
121	Association of Admission to Veterans Affairs Hospitals vs Non-Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 582-92	27.4	59
120	Use of fibrates in the United States and Canada. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 1217-24	27.4	58
119	The importance of clinical trial data sharing: toward more open science. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2012</b> , 5, 238-40	5.8	56
118	Regional variation in cardiac catheterization appropriateness and baseline risk after acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 716-23	15.1	56
117	Variation in US hospital emergency department admission rates by clinical condition. <i>Medical Care</i> , <b>2015</b> , 53, 237-44	3.1	53
116	Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals. <i>Trials</i> , <b>2016</b> , 17, 199	2.8	49

115	Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 297, 1216-23	27.4	47
114	Place of residence and outcomes of patients with heart failure: analysis from the telemonitoring to improve heart failure outcomes trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2014</b> , 7, 749-56	5.8	46
113	Generic atorvastatin and health care costs. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 201-4	59.2	46
112	Promoting transparency in pharmaceutical industry-sponsored research. <i>American Journal of Public Health</i> , <b>2012</b> , 102, 72-80	5.1	46
111	Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation: An Observational Cohort Study. <i>Annals of Internal Medicine</i> , <b>2016</b> , 165, 20-29	8	45
110	Development and Validation of an Algorithm to Identify Planned Readmissions From Claims Data. <i>Journal of Hospital Medicine</i> , <b>2015</b> , 10, 670-7	2.7	43
109	Beyond insurance coverage: usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey. <i>American Heart Journal</i> , <b>2010</b> , 160, 115-21	4.9	43
108	Based on key measures, care quality for Medicare enrollees at safety-net and non-safety-net hospitals was almost equal. <i>Health Affairs</i> , <b>2012</b> , 31, 1739-48	7	39
107	Hospital Characteristics Associated With Risk-standardized Readmission Rates. <i>Medical Care</i> , <b>2017</b> , 55, 528-534	3.1	35
106	Overview and experience of the YODA Project with clinical trial data sharing after 5 years. <i>Scientific Data</i> , <b>2018</b> , 5, 180268	8.2	33
105	Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. <i>Trials</i> , <b>2017</b> , 18, 333	2.8	32
104	The relationship between systolic blood pressure on admission and mortality in older patients with heart failure. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 148-55	12.3	32
103	Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017. <i>JAMA Network Open</i> , <b>2020</b> , 3, e203284	10.4	31
102	Hospital-based, acute care use among patients within 30 days of discharge after coronary artery bypass surgery. <i>Annals of Thoracic Surgery</i> , <b>2013</b> , 96, 96-104	2.7	30
101	Regulatory Review of New Therapeutic Agents - FDA versus EMA, 2011-2015. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1386-7	59.2	29
100	A model for dissemination and independent analysis of industry data. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 306, 1593-4	27.4	28
99	Association of Racial and Socioeconomic Disparities With Outcomes Among Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, and Pneumonia: An Analysis of Within- and Between-Hospital Variation. <i>JAMA Network Open</i> , <b>2018</b> , 1, e182044	10.4	28
98	Poorly cited articles in peer-reviewed cardiovascular journals from 1997 to 2007: analysis of 5-year citation rates. <i>Circulation</i> , <b>2015</b> , 131, 1755-62	16.7	26

97	Patterns and predictors of off-label prescription of psychiatric drugs. <i>PLoS ONE</i> , <b>2018</b> , 13, e0198363	3.7	25
96	US drug marketing: how does promotion correspond with health value?. <i>BMJ, The</i> , <b>2017</b> , 357, j1855	5.9	25
95	Certificate of need regulation and cardiac catheterization appropriateness after acute myocardial infarction. <i>Circulation</i> , <b>2007</b> , 115, 1012-9	16.7	25
94	Characterisation of trials where marketing purposes have been influential in study design: a descriptive study. <i>Trials</i> , <b>2016</b> , 17, 31	2.8	23
93	Comparative Effectiveness of Generic Atorvastatin and Lipitor <sup>®</sup> in Patients Hospitalized with an Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5, e003350	6	23
92	Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform. <i>Npj Digital Medicine</i> , <b>2020</b> , 3, 60	15.7	22
91	Financial stress and outcomes after acute myocardial infarction. <i>PLoS ONE</i> , <b>2012</b> , 7, e47420	3.7	22
90	Association Between Insurance Status and Access to Hospital Care in Emergency Department Disposition. <i>JAMA Internal Medicine</i> , <b>2019</b> , 179, 686-693	11.5	21
89	Hospital variation in risk-standardized hospital admission rates from US EDs among adults. <i>American Journal of Emergency Medicine</i> , <b>2014</b> , 32, 837-43	2.9	20
88	Regional density of cardiologists and rates of mortality for acute myocardial infarction and heart failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2013</b> , 6, 352-9	5.8	20
87	Decision-making and cancer screening: a qualitative study of older adults with multiple chronic conditions. <i>Journal of Geriatric Oncology</i> , <b>2015</b> , 6, 93-100	3.6	19
86	Predictors of clinical trial data sharing: exploratory analysis of a cross-sectional survey. <i>Trials</i> , <b>2014</b> , 15, 384	2.8	19
85	Cardiac Certificate of Need regulations and the availability and use of revascularization services. <i>American Heart Journal</i> , <b>2007</b> , 154, 767-75	4.9	19
84	Time for NIH to lead on data sharing. <i>Science</i> , <b>2020</b> , 367, 1308-1309	33.3	18
83	New and incremental FDA black box warnings from 2008 to 2015. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 117-123	4.1	17
82	Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 1486-93	11.5	16
81	Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. <i>Trials</i> , <b>2018</b> , 19, 581	2.8	16
80	Variation in the Diagnosis of Aspiration Pneumonia and Association with Hospital Pneumonia Outcomes. <i>Annals of the American Thoracic Society</i> , <b>2018</b> , 15, 562-569	4.7	15

79	Correlation of inpatient and outpatient measures of stroke care quality within veterans health administration hospitals. <i>Stroke</i> , <b>2011</b> , 42, 2269-75	6.7	15
78	Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals. <i>Circulation</i> , <b>2019</b> , 140, 379-389	6.7	14
77	Assessment of Preprint Policies of Top-Ranked Clinical Journals. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2011127	10.4	14
76	Age of Data at the Time of Publication of Contemporary Clinical Trials. <i>JAMA Network Open</i> , <b>2018</b> , 1, e181065	10.4	14
75	Usual source of care and outcomes following acute myocardial infarction. <i>Journal of General Internal Medicine</i> , <b>2014</b> , 29, 862-9	4	14
74	Transfer rates from nonprocedure hospitals after initial admission and outcomes among elderly patients with acute myocardial infarction. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 213-22	11.5	14
73	Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada. <i>American Heart Journal</i> , <b>2014</b> , 167, 683-9	4.9	14
72	When choosing statin therapy: the case for generics. <i>JAMA Internal Medicine</i> , <b>2013</b> , 173, 229-32	11.5	14
71	Use of administrative claims models to assess 30-day mortality among Veterans Health Administration hospitals. <i>Medical Care</i> , <b>2010</b> , 48, 652-8	3.1	14
70	Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines. <i>Journal of General Internal Medicine</i> , <b>2018</b> , 33, 651-658	4	13
69	Modernizing the FDA's 510(k) Pathway. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1891-1893	59.2	13
68	Emergency Department Volume and Outcomes for Patients After Chest Pain Assessment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e004683	5.8	13
67	Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 2305-2314	5.6	12
66	Availability of Clinical Trial Data From Industry-Sponsored Cardiovascular Trials. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5, e003307	6	12
65	Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015. <i>Milbank Quarterly</i> , <b>2019</b> , 97, 796-819	3.9	12
64	State-sponsored public reporting of hospital quality: results are hard to find and lack uniformity. <i>Health Affairs</i> , <b>2010</b> , 29, 2317-22	7	12
63	Coronary artery bypass graft: contemporary heart surgery center performance in China. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2012</b> , 5, 214-21	5.8	12
62	State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning. <i>Health Affairs</i> , <b>2012</b> , 31, 188-98	7	12

61	Fulfilling the Promise of Unique Device Identifiers. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, 183-185	8	12
60	Data Desert for Inferior Vena Caval Filters: Limited Evidence, Supervision, and Research. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 3-4	16.2	11
59	Descriptions and interpretations of the ACCORD-Lipid trial in the news and biomedical literature: a cross-sectional analysis. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 1176-82	11.5	10
58	Determinants of cardiac catheterization use in older Medicare patients with acute myocardial infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2010</b> , 3, 54-62	5.8	10
57	A Nationwide Assessment of the Association of Smoking Bans and Cigarette Taxes With Hospitalizations for Acute Myocardial Infarction, Heart Failure, and Pneumonia. <i>Medical Care Research and Review</i> , <b>2017</b> , 74, 687-704	3.7	9
56	Early experience with the FDA's Breakthrough Devices program. <i>Nature Biotechnology</i> , <b>2020</b> , 38, 933-938	14.5	9
55	Risk-standardized Acute Admission Rates Among Patients With Diabetes and Heart Failure as a Measure of Quality of Accountable Care Organizations: Rationale, Methods, and Early Results. <i>Medical Care</i> , <b>2016</b> , 54, 528-37	3.1	9
54	Generic Drugs in the United States: Policies to Address Pricing and Competition. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 329-337	6.1	9
53	Regulatory watch: Characterizing the US FDA's approach to promoting transformative innovation. <i>Nature Reviews Drug Discovery</i> , <b>2015</b> , 14, 740-1	64.1	8
52	Regulatory Review of New Therapeutic Agents. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2598	59.2	8
51	Evaluation of the Anticipated Burden of COVID-19 on Hospital-Based Healthcare Services Across the United States <b>2020</b> ,		8
50	Efficacy and safety concerns are important reasons why the FDA requires multiple reviews before approval of new drugs. <i>Health Affairs</i> , <b>2015</b> , 34, 681-8	7	7
49	Defining Multiple Chronic Conditions for Quality Measurement. <i>Medical Care</i> , <b>2018</b> , 56, 193-201	3.1	7
48	Impact of drug policy on regional trends in ezetimibe use. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2014</b> , 7, 589-96	5.8	7
47	Do imaging studies performed in physician offices increase downstream utilization?: an empiric analysis of cardiac stress testing with imaging. <i>JACC: Cardiovascular Imaging</i> , <b>2011</b> , 4, 630-7	8.4	7
46	Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA. <i>Trials</i> , <b>2020</b> , 21, 675	2.8	7
45	US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018. <i>Clinical Trials</i> , <b>2021</b> , 18, 488-499	2.2	7
44	Merits of Data Sharing: The Digitalis Investigation Group Trial. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1825-1827	15.1	6



43	National quality assessment evaluating spironolactone use during hospitalization for acute myocardial infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4, e001718	6	6
42	Leveraging Open Science to Accelerate Research. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, e61	59.2	6
41	Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. <i>JAMA Internal Medicine</i> , <b>2019</b> , 179, 263-265	11.5	6
40	Data Sharing and Cardiology: Platforms and Possibilities. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 3018-3025	15.1	5
39	Early Experiences With Journal Data Sharing Policies: A Survey of Published Clinical Trial Investigators. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, 586-588	8	4
38	Updated estimates of pharmaceutical company payments to physicians in Vermont. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 300, 1998-2000	27.4	4
37	Accuracy of Computable Phenotyping Approaches for SARS-CoV-2 Infection and COVID-19 Hospitalizations from the Electronic Health Record <b>2021</b> ,		4
36	Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e013606	6	3
35	Physician clinical management strategies and reasoning: a cross-sectional survey using clinical vignettes of eight common medical admissions. <i>BMC Health Services Research</i> , <b>2014</b> , 14, 176	2.9	3
34	Payments for acute myocardial infarction episodes-of-care initiated at hospitals with and without interventional capabilities. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2014</b> , 7, 882-8	5.8	3
33	Direct-to-consumer personal genomic tests need better regulation. <i>Nature Medicine</i> , <b>2021</b> , 27, 940-943	50.5	3
32	Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics. <i>Journal of General Internal Medicine</i> , <b>2020</b> , 35, 1928-1930	4	3
31	Characteristics of available studies and dissemination of research using major clinical data sharing platforms. <i>Clinical Trials</i> , <b>2021</b> , 18, 657-666	2.2	3
30	Having Their Cake and Eating It Too: Physician Skepticism of the Open Payments Program. <i>American Journal of Bioethics</i> , <b>2017</b> , 17, 19-22	1.1	2
29	Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. <i>Thrombosis Research</i> , <b>2020</b> , 186, 78-79	8.2	2
28	Commentary on Bertagnolli et al.: Leveraging electronic health record data for clinical trials-a brave new world. <i>Clinical Trials</i> , <b>2020</b> , 17, 243-246	2.2	2
27	Aggregating Multiple Real-World Data Sources using a Patient-Centered Health Data Sharing Platform: an 8-week Cohort Study among Patients Undergoing Bariatric Surgery or Catheter Ablation of Atrial Fibrillation		2
26	Confidentiality Orders and Public Interest in Drug and Medical Device Litigation. <i>JAMA Internal Medicine</i> , <b>2020</b> , 180, 292-299	11.5	2



25	Medicare's New Device-Coverage Pathway - Breakthrough or Breakdown?. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, e43	59.2	2
24	The Impact of Off-Patent Drug Acquisitions on Prices. <i>Journal of General Internal Medicine</i> , <b>2018</b> , 33, 1007-1009	4	1
23	Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies. <i>Journal of General Internal Medicine</i> , <b>2019</b> , 34, 2319-2321	4	1
22	Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA. <i>Trials</i> , <b>2021</b> , 22, 817	2.8	1
21	Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis		1
20	Clinical Evidence Supporting FDA Clearance of First-of-a-Kind Therapeutic Devices via the De Novo Pathway Between 2011 and 2019		1
19	U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018		1
18	Unplanned Hospital Visits after Ambulatory Surgical Care		1
17	Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use. <i>Endocrine</i> , <b>2021</b> , 74, 592-602	4	1
16	Commentary: Diagnostic devices in clinical trials have high stakes for patient care. <i>BMJ, The</i> , <b>2016</b> , 354, i5197	5.9	1
15	Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017. <i>Research Integrity and Peer Review</i> , <b>2019</b> , 4, 26	6.1	1
14	Impact of left ventricular assist devices and heart transplants on acute myocardial infarction and heart failure mortality and readmission measures. <i>PLoS ONE</i> , <b>2020</b> , 15, e0230734	3.7	1
13	Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 848-856	2.6	1
12	Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation. <i>Clinical Trials</i> , <b>2021</b> , 18, 732-740	2.2	1
11	Quality of Care in the United States Territories, 1999-2012. <i>Medical Care</i> , <b>2017</b> , 55, 886-892	3.1	0
10	Rates of, and factors associated with, switching among generic levothyroxine preparations in commercially insured American adults.. <i>Endocrine</i> , <b>2022</b> , 1	4	0
9	Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015. <i>Ophthalmology</i> , <b>2017</b> , 124, 1237-1246	7.3	0
8	Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010-2020. <i>Journal of General Internal Medicine</i> , <b>2021</b> , 1	4	0

7	Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population. <i>BMJ Open</i> , <b>2018</b> , 8, e021685	3	o
6	A multicenter evaluation of computable phenotyping approaches for SARS-CoV-2 infection and COVID-19 hospitalizations.. <i>Npj Digital Medicine</i> , <b>2022</b> , 5, 27	15.7	o
5	Conflicts of interest, authorship, and disclosures in industry-related scientific publications. <i>Mayo Clinic Proceedings</i> , <b>2010</b> , 85, 199-200; author reply 201-4	6.4	
4	Clinical studies sponsored by digital health companies participating in the FDA's Precertification Pilot Program: A cross-sectional analysis. <i>Clinical Trials</i> , <b>2021</b> , 17407745211048493	2.2	
3	Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials. <i>Clinical Trials</i> , <b>2020</b> , 17, 723-728	2.2	
2	Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluation. <i>BMJ Open</i> , <b>2019</b> , 9, e025936	3	
1	Physician Network Connections Associated With Faster De-Adoption of Dronedronone for Permanent Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2021</b> , 14, e008040	5.8	